Tonix Pharmaceuticals Holding Corp.

Contributing Author

Recent Articles by Tonix Pharmaceuticals Holding Corp.

Nov-17	Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment TNXP GlobeNewswire
Nov-10	Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights TNXP GlobeNewswire
Nov-06	Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference TNXP GlobeNewswire
Nov-04	Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection TNXP GlobeNewswire
Oct-28	Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025 TNXP GlobeNewswire
Oct-27	Tonix Pharmaceuticals Presented Data on Tonmya (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence TNXP GlobeNewswire
Oct-22	Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital TNXP GlobeNewswire
Oct-21	Tonix Pharmaceuticals to Present Poster on Tonmya at the 2025 American College of Rheumatology (ACR) Convergence TNXP GlobeNewswire
Oct-17	Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress-Europe 2025 TNXP GlobeNewswire
Oct-14	Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation TNXP GlobeNewswire
Oct-09	Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 TNXP GlobeNewswire
Sep-30	Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access TNXP GlobeNewswire
Sep-29	Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 TNXP GlobeNewswire
Sep-18	Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder TNXP GlobeNewswire
Sep-17	Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) TNXP GlobeNewswire
Sep-08	Tonix Pharmaceuticals Presents Clinical Data on Tonmya for the Treatment of Fibromyalgia at PAINWEEK 2025 TNXP GlobeNewswire
Aug-28	Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025 TNXP GlobeNewswire
Aug-15	Tonix Pharmaceuticals Announces FDA Approval of Tonmya (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia TNXP GlobeNewswire
Aug-11	Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights TNXP GlobeNewswire
Jul-21	Tonix Pharmaceuticals Announces the Launch of the "Move Fibro Forward" Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia TNXP GlobeNewswire
Jul-10	Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 TNXP GlobeNewswire
Jul-09	Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine TNXP GlobeNewswire
Jul-07	Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025 TNXP GlobeNewswire
Jul-02	Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models TNXP GlobeNewswire
Jun-30	Tonix Pharmaceuticals Announces Inclusion in the Russell 3000 and Russell 2000 Indexes TNXP GlobeNewswire
Jun-16	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 TNXP GlobeNewswire
Jun-13	Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors TNXP GlobeNewswire
Jun-10	Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention TNXP GlobeNewswire
Jun-05	Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 TNXP GlobeNewswire
May-22	Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase TNXP GlobeNewswire
May-21	Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction TNXP GlobeNewswire
May-14	Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations TNXP GlobeNewswire
May-12	Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights TNXP GlobeNewswire

Tonix Pharmaceuticals Holding Corp.

Recent Articles by Tonix Pharmaceuticals Holding Corp.

Upgrade your FINVIZ experience